Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Information source: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: Intraductal arm (Drug); Intravenous arm (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Sidney Kimmel Comprehensive Cancer Center Official(s) and/or principal investigator(s): Vered Stearns, MD, Study Chair, Affiliation: Sidney Kimmel Comprehensive Cancer Center
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill
more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed.
PURPOSE: This phase I trial is studying the side effects and best dose of liposomal
doxorubicin when given before mastectomy in treating women with invasive breast cancer.
Clinical Details
Official title: A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum Tolerated Dose (MTD)
Secondary outcome: Concentrations of Doxorubicin in Blood (Plasma) at Definitive SurgeryConcentrations of Doxorubicin in Tissue at Definitive Surgery
Detailed description:
OBJECTIVES:
Primary
- Evaluate the feasibility, safety, and maximum tolerated dose of intraductal pegylated
doxorubicin HCl liposome in women with invasive breast cancer awaiting mastectomy.
Secondary
- Determine the pharmacokinetics of intraductal pegylated doxorubicin HCl liposome,
including serial plasma concentrations of doxorubicin and doxorubicinol and tissue
concentrations in different portions of the breast at the time of surgery.
OUTLINE: This is a dose-escalation study.
Patients receive an intraductal injection of pegylated doxorubicin HCl liposome* on day 1.
Patients undergo mastectomy 2-4 weeks later.
Cohorts of 3-6 patients receive escalating doses of pegylated doxorubicin HCl liposome*
until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose
preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At
least 6 patients are treated at the MTD.
NOTE: *The first cohort of 3 patients receive intraductal dextrose only followed by surgery
as a feasibility study. An additional 3 patients receiving intravenous PLD will be enrolled
in a pharmacokinetic control portion of the study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
DISEASE CHARACTERISTICS:
- Histologically confirmed infiltrating carcinoma of the breast meeting any of the
following criteria:
- T1-3, any N disease
- Proven ductal carcinoma in situ
- Unresected disease
- Planned mastectomy as definitive surgical procedure
- Known or suspected metastatic disease allowed provided mastectomy is
planned
- Nonpalpable tumor allowed (e. g., initial T2-3 tumor that responded to preoperative
therapy)
- No inflammatory breast cancer or other T4 features
- Successful baseline ductogram
- Baseline nipple aspiration procedure must identify a duct productive of nipple
aspirate fluid
- No severe nipple retraction
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Female patients
- Menopausal status not specified
- ECOG performance status 0-2
- Absolute neutrophil count ≥1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9. 0 g/dL
- Creatinine ≤ 2 times upper limit of normal (ULN)
- Bilirubin ≤ 2 times ULN
- AST and ALT ≤ 2. 5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No significant history of severe allergy to iodinated contrast material or
debilitating anxiety that may not allow for a ductogram
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy
allowed provided it was completed 7-14 days prior to study treatment
- No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or
breast implant (present or past history of implant that was removed)
- No other prior procedure that may have altered the breast ductal system in the
ipsilateral breast
- No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents
for breast cancer
- No other concurrent investigational drugs
- Concurrent bisphosphonates allowed
Locations and Contacts
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202-5289, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-2410, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: November 2005
Last updated: October 7, 2013
|